PB2060: THE MDS-SPECIFIC COMORBIDITY INDEX (MDS-CI) PREDICTS SURVIVAL INDEPENDENTLY FROM DIPSS AND MIPSS70 IN PATIENTS WITH OVERT MYELOFIBROSIS NOT ELIGIBLE FOR ALLOGENEIC STEM CELL TRANSPLANTATION.
K.-L. Koster,
N.-M. Messerich,
T. Volken,
S. Cogliatti,
T. Lehmann,
A. Holbro,
R. Benz,
L. Graf,
I. Demmer,
W. Jochum,
T. Silzle
Affiliations
K.-L. Koster
1 Clinic for Medical Oncology and Hematology
N.-M. Messerich
2 Departement of Intensive Care, Cantonal Hospital St. Gallen, St. Gallen
T. Volken
3 Institute of Public Health, ZHAW School of Health Sciences, Winterthur
S. Cogliatti
4 Institute of Pathology, Cantonal Hospital St. Gallen, St. Gallen
T. Lehmann
1 Clinic for Medical Oncology and Hematology
A. Holbro
5 Division of Hematology, University Hospital Basel, Basel
R. Benz
6 Clinic for Hematology and Oncology, Spital Thurgau AG, Münsterlingen
L. Graf
7 Centre for Laboratoty Medicine, St. Gallen, Switzerland
I. Demmer
4 Institute of Pathology, Cantonal Hospital St. Gallen, St. Gallen
W. Jochum
4 Institute of Pathology, Cantonal Hospital St. Gallen, St. Gallen
